Showing posts with label Congress. Show all posts
Showing posts with label Congress. Show all posts

Wednesday, May 9, 2007

Cheap Prescription Drugs Denied Access

"The Senate Guts Drug Bill." Trouthout

As usual, might won over right. Last time I posted here about proposed amendments to the PDUFA. Well, true to form, the United States Senate voted to not allow the importation of cheaper prescription drugs from Canada and other countries. The stated basis of this voting was that the Food and Drug Administration cannot certify the imports would be safe and effective.

This vote is justified to the extent that the FDA does not have and cannot afford the resources to create the bureaucracy that would be required by a certification procedure. However, this defense is a strawman specifically erected so that it could be knocked down. If imports were accepted, there would be no need to certify them as safe since those drugs would have already been approved by the FDA. One sponsor of the bill went as far as to assert: "arguments that imports would open the door to dangerous counterfeits are nonsense perpetrated by big drug companies protecting their profits."

I agree. There is also the millions in user fees the FDA collects for reviewing applications from pharmaceutical companies. Permitting the re-importation of cheap, American prescription drugs is not the purpose of the current review of the Prescription Drug User fee Act, scheduled to expire in September. Rather, the sole purpose is to provide for continuation and substantially increase of the user fees paid to the FDA. Thus we see that the cheap drug re-import debate was merely a smokescreen engineered to distract from the real reasons for review of the statute.

Friday, April 20, 2007

Medicare Drug Price Negotiation Stalled

"Democrats failed Wednesday to get the 60 U.S. Senate votes they needed to proceed with a bill to give Medicare the power to negotiate lower drug prices for millions of older Americans" - HealthDay.com

Yesterday's post described how pharmaceutical giant Amgen, Inc. and for-profit dialysis chains were raking in millions of dollars as a result of the flawed reimbursement payment system, administered by Medicare, with respect to the drugs Aransep, Epogen and Procrit. One could therefore assume it would be an easy matter to reduce or discontinue the unhealthy profits. But it does appear it will be a difficult, long battle to withdraw the candy. Why? Current law forbids Medicare from negotiating drug prices with pharmaceutical companies!

The 2003 Medicare Modernization Act overhauled medicare and medicaid so as to provide seniors and individuals with disabilities with a prescription drug benefit, more choices, and better benefits under Medicare. This legislation specifically prohibits the Secretary of Health and Human Services, HHS, from participating in price negotiations for the Medicare prescription drug benefit.

On January 12, 2007, the House approved the Medicare Prescription Drug Price Negotiation Act of 2007 (H.R.4), with the specific intention of reversing the non-negotiation clause in the 2003 legislation. H.R.4 mandated that the HHS Secretary negotiate lower drug prices – including discounts, rebates and other price concessions – for sponsors of Part D prescription drug or Medicare Advantage plans. Over the years, Part D was credited with lowering drug prices, but Democrats felt costs could be further reduced by permitting Medicare to negotiate directly with drugmakers.

Under Medicare Part D, which covers the cost of most prescription drugs for elderly patients, insurers negotiate directly with the pharmaceutical industry and receive a federal subsidy for administering a drug plan. Oddly enough, although H.R.4 required the HHS Secretary to act, the second paragraph in the legislation states: “Nothing in paragraph (1) shall be construed to authorize the Secretary to establish or require a particular formulary.” In layman's terms, this means the Secretary would have no authority to set up a preferred list of drugs for which Medicare will pay. Without such a list, or the threat of keeping some drugs off the formulary, drug companies would have no particular incentive to cut their prices.

On April 13th, the Senate Finance Committee approved an amendment [S.3] to H.R.4, which amendment withdrew the language in the 2003 Medicare Modernization Act that prohibits the HHS Secretary from participating in drug price negotiations and, in addition, "allowed" doctors and patients to compare the effectiveness of drugs and other medical treatments.

On April 18th, S.3 was reviewed in the Senate and Republicans blocked the mostly Democrat proposal to permit Medicare to negotiate drug prices directly with pharmaceutical companies, despite reports [see House Speaker Nancy Pelosi's statement here] that for the top 15 drugs prescribed for seniors, the median Medicare Part D price has skyrocketed in the last year, growing by 9.2 percent, almost four times the inflation rate of 2.4 percent.

Republicans claimed S.3 would "impede competition and reduce convenience for beneficiaries." HHS Secretary Mike Leavitt also stated that permitting a government authority to negotiate drug prices could lead to price controls in a future presidential administration. My sense is that the non-negotiation clause favors lining the pockets of the powerful insurance and pharmaceutical companies and that the latter's lobbyists were likely responsible for this outcome. Second, it is unclear why S.3 was so vehemently opposed as it had no teeth - it merely sought to "allow" as opposed to "require" the HHS secretary to negotiate the drug prices. In all likelihood therefore, the war on high drug prices will continue.